Unprecedented Phase 1 CML efficacy data and potential best-in-disease profile of TERN-701 featured in ASH 2025 abstract Upcoming ASH oral ...

More about CML Microsystems. CML Microsystems Plc develops mixed-signal, RF, and microwave semiconductors for global comm ...

A lower number of CD26+ LSCs at diagnosis correlates with optimal molecular response in CML patients at 3, 12, and 24 months.

Unprecedented Phase 1 CML efficacy data with 64% MMR achievement by 24 weeks in a refractory patient population Encouraging safety and tolerability profile at all doses evaluated Company to host ...

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced ...

Lucknow: Chronic Myeloid Leukemia (CML) — which forms a major share of adult blood cancer cases in Uttar Pradesh — can now be ...

Alembic Pharma received USFDA approval for its generic Dasatinib Tablets (20–140 mg), equivalent to Sprycel by BMS. The drug ...

For patients living with CML, every diagnosis marks the start of a journey shaped by fear, resilience and, above all, hope.

Chicago Magic Lounge will present the debut of Magic is People, a new one-man show by founding company member and audience ...

Terns Pharmaceuticals (TERN) is getting attention after announcing that early-stage trial results for its CML drug candidate, TERN-701, were selected for oral presentation at this year's American ...

The company announced that data from the ongoing CARDINAL trial of TERN-701 in participants with previously treated chronic myeloid leukemia (CML) will be presented at the 67th American Society of ...